BASEL, Switzerland,
Sept. 30 /PRNewswire-FirstCall/ -
Neuro-Biotech Corporation (PINKSHEET: MRES)(OTCQB:MRES) in
acquiring licenses to commercialize 12 Neuro-biomarkers has first
focused on SymPath(R) and is now ready to give you the opportunity
to shed some light about this Neuro-biomarker of the Sympathetic
Nervous System (SNS). Here is a peak into the research behind the
Neuro-blood testing that will be available to all patients through
their health system.
It is important to pinpoint that DBH was first described in 1955
and reviewed in 1965 by Kaufman & Friedman. In 1974, Geffen has
described DBH as a biomarker of the SNS. At that moment, in the
Journal of Neurochemistry, Roberge et al. (1976) have published
that an inversed relationship occurs between the brain dopamine and
serotonin content on a neuroanatomical basis. As in the brain, the
noradrenergic and serotoninergic pathways are closed together at
the level of the locus coereleus, the raphei nuclei and the
brainstem, respectively (Roberge & Poirier, 1973, 1974) and
that, to an increased dopamine content following the administration
of L-DOPA in monkeys did not correspond to increased noradrenaline
content within several neuroanatomical structures in the brain.
Moreover, it was demonstrated that DBH was involved in anxiety and
depression (Friedman et al., 1984).
In this respect, working with 15 to 18 different brain
structures, the effects observed in the structures related to the
motor system were different to those noted within the mesolimbic
system - it was the starting point to understand how DBH is working
to be the key enzyme in the noradrenaline synthesis.
The kinetic DBH enzyme activity and biochemical parameters were
respectively studied in the brain, adrenals and blood of different
species such as monkeys, cats, rats, rabbits, fish, mink, sheep and
human beings using various stressful situations and several drugs.
In this respect, Parkinson Disease, Alzheimer, Schizophrenia and
stress related diseases were respectively studied working with
catecholaminergic, serotoninergic and cholinergic pathways related
to the motor system (monkeys), to the memory mechanisms (cats),
learning disabilities (human beings), anorexia nervosa (human
beings), bulimia (developing a model with rats in regards to people
waiting for bypass surgery). As the relationship between the brain
and the HPAS Axis is a key issue in stress related diseases,
various stressful situations such as, cold exposure, immobilization
and treadmill in rats, hypoxia in fish, a workload in a swimming
pool in humans, food behaviours using cats, rabbits, rats, minks
and fishes. Finally, in rats, the effects of spontaneously
hypertensive state on DBH enzyme activity were compared to clinical
data obtained from a group of post MI people.
DBH, the synthesising enzyme of noradrenaline from dopamine, is
a copper and ascorbate dependent. Noradrenaline, a vasoconstrictor,
is released within the blood from the SNS with DBH. Its biochemical
and kinetic parameters were studied in brain, adrenals and serum
(Fortin & Roberge, 1992) and in human beings to figure out how
a commercial kit could be useful for different clinical purposes on
a daily basis (US Patent (#5879902) and Canadian Patent (#
2204179)). In human beings, several studies were conducted
involving different sexes, age, Rhesus factor, blood groups,
seasonal variations, diurnal rhythms and endocrine functions..
In summary, noradrenaline, a vasoconstrictor, is released within
the blood from the SNS with DBH. A commercial kit named SymPath(R)
has been developed to quantitatively standardize the measurement
kit of the specific activity of DBH released within the blood from
the SNS. In this regards, the clinical data allow to distinguish
anxious disorders from depressive disorders - that is a
breakthrough in neurosciences.
Contact:
Neuro-Biotech Corp.
Dr Claude Poulin
41 61 500 05 16
info@neuro-agora.com
www.neuro-biotechcorp.com
SOURCE Neuro-Biotech Corp.
Copyright . 30 PR Newswire